BOSTON and rolle, Swiss,, April 29, 2025 / Prnewswire / – Sophia Genetics (NASDAQ: SOPH), a native health technology company and a world leader in data -based medicine, announced today the expansion of its current collaboration with Astrazeneca (LSE / STO / NASDAQ: AZN) to accelerate the deployment of MSK -ACCESS® with Sophia DDM ™. Based on the initial collaboration announced in October 2024This new phase will extend the scope of the test to a total of 30 clinical institutions worldwide in 2025.
Developed in collaboration with Memorial Sloan Kettering Cancer Center, MSK-ACCESS® powered with Sophia DDM ™ is an innovative liquid biopsy test application designed to detect exploitable genomic alterations in a single blood sample using cutting-edge algorithms of the technology that analyze the circulating tumor. The application supports the monitoring of cancer in real time and the selection of treatment when traditional tissue biopsies are not achievable due to the cost, execution time, insufficient tissue or the invasiveness of the procedure.
The enlarged deployment will continue to contribute to the global initiatives of real evidence of Astrazeneca and helps to further validate the clinical impact of decentralized liquid biopsy tests through various health systems. By increasing the availability of MSK-Access® supplied with Sophia DDM ™, Sophia Genetics and Astrazeneca aim to better understand how liquid biopsy tests can complete solid tests and, in some cases, offer greater advantage to laboratories and patients.
The announcement coincides with the presentation of Sophia Genetics in Aacr, in which the company presented data demonstrating the solid transferability of the decentralized MSK-ACCESS® with Sophia DDMTM solution. Historically, site discrepancy was a major obstacle to the generalized adoption of liquid biopsy tests. Sophia Genetics presented real data highlighting the coherent accuracy and precision of MSK-Access® powered with Sophia DDMTM in various laboratory contexts. The provisional results of the multicenter study have demonstrated the high analytical performance of the decentralized test in accordance with the original test with unique site at the Memorial Sloan Kettering Cancer Center in new York.
“Our collaboration with Astrazeneca represents an important step towards scaling new generation oncology diagnostics on a global scale,” said Ross MukenPresident, Sophia Genetics. “This extended deployment reflects the growing momentum of liquid biopsy and our common ambition to make these technologies more accessible and impactful worldwide.”
Visit Sophia Genetics to the annual meeting of the American Association for Cancer Research in Chicago, Illinois Since April 25th–30th To find out more about how Sophia Genetics collaborates with Astrazeneca to transform patient care with data -based drugs.
For more information on Sophia Genetics, visit Sophiagenetics.comor connect to Liendin.
About Sophia Genetics
Sophia Genetics (NASDAQ: SOPH) is a native cloud health technology company to extend access to data -based drugs using AI to provide world class care to cancer and rare disorders around the world. It is the creator of the Sophia DDM ™ platform, which analyzes complex genomic and multimodal data and generates real and usable information for a large global network of hospital, laboratories and biopharmatic institutions. For more information, visit Sophiagenetics.com And connect with us on Liendin.
Sophia Genetics products are for the use of research only and not for use in diagnostic procedures, unless otherwise indicated. Information in this press release concerns products that may or may not be available in different countries and, if necessary, may or may not have received the approval or the authorization of the market by a government regulatory body for various user indications. Please contact support@sophiagenetics.com For information on products appropriate for your country of residence.
Sophia Genetics Award Award Award:
This press release contains statements that constitute prospective statements. All declarations other than the declarations of the historical facts contained in this press release, including the declarations concerning our results of operations and the financial situation, commercial strategy, products and technology, as well as management plans and objectives for future operations, are prospective declarations. Prospective declarations are based on the beliefs and assumptions of our management and on the information currently available for our management. These declarations are subject to risks and uncertainty, and real results may differ materially from those expressed or implicit in prospective declarations due to various factors, including those described in our files with the Securities and Exchange American Commission. No insurance can be given that such future results will be obtained. These prospective declarations contained in this press release only speak of the date of these. We expressly decline any obligation or engaging to update these prospective declarations contained in this press release to reflect any change in our expectations or any change in the events, the conditions or the circumstances on which these declarations are founded, unless you do by applicable law. No representation or guarantee (expressed or implicit) is made on the accuracy of these prospective declarations.
Media contact:
media@sophiagenetics.com
Source Sophia Genetics
